-
-
YYY - The thread titled 'Something New', people start discussing it about halway through I think.
Dr Yates - Thank you for responding
Comment
-
It will be available in Colombia by end of year. If it ends up being something, I'll try it out and provide a review.Comment
-
It makes you wonder - why doesn't histogen do this?The Wall Street Journal news department was not involved in the creation of this content.
PRESS RELEASEJuly 1, 2013, 10:10 a.m. ET
Biologix Hair Inc. Set to Launch Commercial Treatment Operations, Opening Prototype Certified Biologix Hair Therapy Center(TM)
EmailPrinter
FriendlyShare:
facebook
↓ More
Text
Biologix Hair Inc. Set to Launch Commercial Treatment Operations, Opening Prototype Certified Biologix Hair Therapy Center(TM)
TORONTO, ONTARIO--(Marketwired - July 1, 2013) - Biologix Hair Inc. (OTCBB:BLGX)(OTCQB:BLGX) is pleased to report that the company's wholly owned subsidiary, Biologix Hair Science Ltd.(TM), intends to open a company-owned and -operated certified Biologix Hair Therapy Center(TM) in Cartagena, Colombia before the end of October, 2013.
In addition to offering Biologix's patent pending hair loss therapy commercially for the first time and enabling Biologix to start generating revenues, the treatment facility will serve as a training center for licensed clinicians who've contracted with Biologix to operate certified Biologix Hair Therapy Centers(TM) and a prototype for future clinics, not operated by Biologix but by these certified clinicians.
In a news release dated May 31, 2013 entitled "Biologix Hair Inc. Reports New Clinician Licensing Numbers; Network Expands to 276 Clinics in 38 Countries; Captive Patient Universe Grows 264% to 3,284,065 People" Biologix reported that as of April 30, 2013 it had contracted with 276 operating clinics located in 38 countries. The total number of existing patients treated by this international network over the past five years is 3,284,065 with the contracting clinicians estimating that 1,315,926 of these patients would be interested in either the hair loss prevention or hair loss regeneration treatment and are candidates for the Biologix Hair Therapy System(TM).
Dr. Diego Castresana, Vice President of Research and Development for Biologix Hair Science Ltd.(TM), commented: "Cartagena is the ideal location for us to launch our initial commercial operations. There are no regulatory hurdles to overcome and it is in the general area where many of the pre-clinical-trial patients were treated. Management is in the final stages of determining the ideal location within the city for our clinic and I look forward to being able to make that announcement within the next couple of weeks.
"Being based here allows me to personally oversee clinic operations to ensure the highest standards possible are continually met. And with direct flights from major worldwide airports, it is also convenient for medical practitioners to attend and receive formal training. Cartagena is a safe, beautiful, modern resort city of approximately one million people that offers individuals seeking treatment and clinicians receiving training a splendid backdrop for leisure and an opportunity to explore the charm and majesty that this Caribbean destination has to offer - an added benefit to their treatment or training experience."
Historical Pre-Clinical Success
From 2004 to late 2011, before the acquisition of the worldwide intellectual property rights by Biologix Hair Science Ltd.(TM), more than 30,000 pre-clinical-trial treatments of the Biologix Hair Therapy System(TM) were administered to 5,000+ patients in scientifically controlled environments by Dr. Duran and a dedicated team of private clinicians located throughout South America.
During those eight years, the clinicians subjectively estimated that healthy hair growth has been maintained in virtually 100% of the people whose goal was to prevent the onset of Follicle Nutrient Deficiency Syndrome (FNDS) and resulting alopecia.
The clinicians estimate that between 80 - 85% of their male patients and upwards of 90% of their female patients being treated for FNDS and seeking hair regeneration therapy have been able to regrow their lost hair. Video testimonials offered by some of these hair regeneration patients are available here: http://www.Biologixhair.com/results/hair-regeneration.
Of the alopecia areata patients - both men and women - the rate of success has been observed to be nearly 100%. Alopecia areata testimonials can be found here: http://www.biologixhair.com/results/alopecia-areata.
Over these eight years, no negative side effects have been reported.
Preparing For Global Commercial Success
Biologix is now ready to make this groundbreaking hair restoration and hair loss prevention therapy available for the first time.
While Biologix Hair Inc., together with wholly owned subsidiary companies operated by Biologix Hair Science Ltd.(TM), works to obtain FDA approval and subsequent approvals in major markets, Biologix has simultaneously been developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists(TM) and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System(TM).
Although the Biologix Hair Therapy System(TM) is currently not able to be offered in more heavily regulated markets, such as the United States, Canada and the European Union, there are several countries and regions with less restrictive regulatory barriers that enable Biologix to accelerate the regulatory approval process and initiate the availability of treatment via its rapidly expanding international network of certified clinicians - Colombia being one of them. And that is where the Company will headquarter its initial fee-for-service operations. At this time, the Company will actively market only to citizens in such areas and will not market to or encourage travel by citizens of regions where the Biologix Hair Therapy System(TM) has not yet been approved by regulatory agencies.
Growing Revenues Through Our Licensed Clinician Network
The Colombia-based clinic will utilize the same Biologix Revive formula and techniques employed by treatment clinicians during the pre-clinical trials that were carried out by the original inventor group.
Upon completion of the standardization work currently well underway with the Beijing Institute of Technology (BIT) and the filing of our final formulation with the US Patent and Trademark Office, Biologix should be ready to start utilizing the standardized vials in its prototype clinic and be ready to commence shipment of Biologix Revive to licensed clinics operating in less regulated markets where regulatory approvals are obtainable.
Biologix management is currently working together with its Medical Advisory Board and its team of legal advisors to determine in which strategic locations around the world to allow Certified Biologix Hair Therapists(TM) to begin offering commercial treatment options - expected to begin before the end of the first quarter of 2014.
Biologix CEO Michael Stocker stated: "We have worked very diligently over the past couple of years to build a long-term business plan that leverages the benefits of licensing our technology for application by top medical practitioners and clinicians around the world. As the demand for certification continues to grow, it is now time for us to capitalize on the revenue potential available for this revolutionary hair loss solution in welcoming markets.
"Clearly, our eye is fixed on securing regulatory approvals in all commercially desirable markets, such as the major Western markets, but there is no reason to postpone the ability to start rolling out treatment locations all over the world where we have the opportunity to do so right now. And that is exactly what we intend to do."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. (TM) (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System(TM) - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and late 2011, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System(TM) - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 147 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System(TM) and is rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists(TM) and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System(TM).
Although the Biologix Hair Therapy System(TM) is currently not able to be offered in more heavily regulated markets, such as the United States, Canada and the European Union, there are countries and regions with less restrictive regulatory barriers that enable Biologix to provide immediate treatment via its clinician network while simultaneously focusing on obtaining regulatory approvals for all markets, worldwide.
BHS is in the process of opening a prototype commercial hair therapy treatment and medical training center in Cartagena, Colombia. The fee-for-service clinic is expected to be operational before the end of October 2013. Additionally, management is currently working together with its Medical Advisory Board and its team of legal advisors to determine in which strategic locations around the world to begin offering commercial treatment options - expected to be available in the first quarter of 2014.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
Disclaimer
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.
Biologix Hair Inc.
Corporate Communications
Toll Free: +1 855.292.8585
Phone: +1 647.494.8001
CorporateCommunications@BiologixHair.com
Comment
-
Where does it mention MALE PATTERN BALDNESS ?Comment
Tweet
Comment